Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreDrugs Formulary for District Hospitals - Ethiopia (DACA; 2004; 322 pages)
Afficher le documentACKNOWLEDGEMENTS
Afficher le documentINTRODUCTION
Afficher le documentGENERAL ADVICE TO PRESCRIBERS
ouvrir ce répertoire et afficher son contenu1. DRUGS ACTING ON THE GASTROINTESTINAL SYSTEM
ouvrir ce répertoire et afficher son contenu2. CARDIOVASCULAR DRUGS
ouvrir ce répertoire et afficher son contenu3. RESPIRATORY DRUGS
ouvrir ce répertoire et afficher son contenu4. CENTRAL NERVOUS SYSTEM DRUGS
ouvrir ce répertoire et afficher son contenu5. DRUGS USED IN ANESTHESIA
ouvrir ce répertoire et afficher son contenu6. DRUGS USED IN MUSCLOSKELETAL AND JOINT DISEASE
ouvrir ce répertoire et afficher son contenu7. ANTI-INFECTIVE
ouvrir ce répertoire et afficher son contenu8. DRUGS USED IN ENDOCRINE DISORDERS AND CONTRACEPTIVES.
Afficher le document9. OBSTETRIC AND GYNAECOLOGICAL MEDICATIONS
ouvrir ce répertoire et afficher son contenu10. BLOOD PRODUCTS AND DRUGS AFFECTING THE BLOOD
ouvrir ce répertoire et afficher son contenu11. DRUGS FOR CORRECTING WATER, ELECTROLYTE AND ACID - BASE DISTURBANCES
ouvrir ce répertoire et afficher son contenu12. VITAMINS
fermer ce répertoire13. ANTIHISTAMINES AND ANTIALLERGICS
Afficher le document13.1. Antihistamines
Afficher le document13.2. Drugs used in Allergic Emergencies
ouvrir ce répertoire et afficher son contenu14. OPHTHALMIC AGENTS
ouvrir ce répertoire et afficher son contenu15. EAR, NOSE, AND THROAT PREPARATIONS
ouvrir ce répertoire et afficher son contenu16. DERMATOLOGIC AGENTS
Afficher le document17. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
Afficher le document18. IMMUNOLOGICAL PREPARATIONS
Afficher le document19. MISCELLANEOUS
Afficher le documentAPPENDIXES
Afficher le documentGLOSSARY
Afficher le documentBACK COVER
 

13.2. Drugs used in Allergic Emergencies

Anaphylactic shock and conditions such as angioedema are medical emergencies that can result in cardiovascular collapse and/or death. They require prompt treatment of possible laryngeal edema, bronchospasm or hypertension. Atopic individuals are particularly susceptible. Insect bites and certain foods including eggs, fish, peanuts and nuts are also a risk for sensitized persons. Therapeutic substances particularly associated with anaphylaxis include blood products, vaccines, hyposensitizing (allergen) preparations, antibiotics (especially penicillins), iron injections, heparin, and neuromuscular blocking drugs. Acetyl salicylic acid and other non-steroidal anti-inflammatory drugs (NSAIDs) may cause bronchoconstriction in leukotriene-sensitive patients. In the case of drug allergy, anaphylaxis is more likely to occur after parenteral administration. Resuscitation facilities should always be available when injecting a drug associated with a risk of anaphylactic reactions.

First line treatment of a severe allergic reaction includes administering epinephrine (adrenaline), keeping the airway open (with assisted respiration if necessary) and restoring blood pressure. Epinephrine (adrenaline) should immediately be given by intramuscular injection to produce vasoconstriction and bronchodilation and injections should be repeated every 10 minutes until blood pressure and pulse have stabilized. If there is cardiovascular shock with inadequate circulation, epinephrine (adrenaline) must be given cautiously by slow intravenous injection of a dilute solution. An intravenous corticosteroid e.g. hydrocortisone (as sodium succinate) in a dose of 100 - 300 mg is of secondary value in the initial management of anaphylactic shock because the onset of action is delayed for several hours, but should be given to prevent further deterioration in severely affected patients.

Adrenaline (Epinephrine)
Injection, 0.1 % in 1 ml ampoule

Indications: - emergency treatment of acute anaphylaxis; angioedema; cardiopulmonary resuscitation; see also section 2.5 and 3.2 for other uses of Adrenaline

Cautions: - hyperthyroidism, diabetes mellitus, heart disease, hypertension, arrhythmias, cerebro-vascular disease, angle-closure glaucoma, second stage of labor, elderly patients.

Side effects: anxiety, tremor, tachycardia, arrhythmias, headache, cold extremities; also hypertension (risk of cerebral hemorrhage) and pulmonary edema (on excessive dosage or extreme sensitivity) nausea, vomiting, sweating, weakness, dizziness, and hyperglycemia also reported

Dose and Administrations

Caution: Different dilutions of epinephrine injection are used for different routes of administration

Intramuscular or subcutaneous injection use 1:1000 epinephrine injection.

Slow intravenous injection use 1:10 000 epinephrine injection.

This route should be reserved for severely ill patients when there is doubt about the adequacy of circulation and absorption from the intramuscular site.

Hydrocortisone
Injection (sodium succinate),50 mg/ml in 2 ml ampoule

Indications: - used for life-threatening shock only after less toxic therapies have proven ineffective.

Cautions: - pregnancy and in children; in patients with hypothyroidism or cirrhosis, psychosis, hypertension, congestive heart failure, diverticulitis, HIV, herpes simplex, oral herpetic lesions, renal function impairment or disease, tuberculosis, diabetes mellitus.

Drug-interactions: - alcohol, acetaminophen, non-steroidal anti-inflammatory drugs, parenteral amphoterecin B, atropine, oral antidiabetic agents or insulin, digitalis glycoside, diuretics, isoniazid.

Contraindications: - known hypersensitivity to any of corticosteroids, recent surgery, osteoporosis, scleroderma, Cushing's syndrome.

Side effects: - immunosuppression, muscle pain or weakness, delayed wound healing, edema, hypertension, cataract, diabetes mellitus, nausea, vomiting, anorexia, headache, vertigo, insomnia, restlessness, acne, impaired wound healing, increased sweating, hirustism.

Dose and Administration:

Adult dose - for life threatening shock IV-massive dose 50mg/kg initially and repeated in 4 hours and/or every 24 hours if needed, or 0.5-2g IV initially and repeated at 2 to 6 hours intervals as required.

Storage: - at room temperature.

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires Anglais  |  Français